Thompson Siegel & Walmsley’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.03M Buy
121,984
+66,080
+118% +$3.79M 0.13% 185
2026
Q1
$3.39M Buy
55,904
+43,750
+360% +$2.55M 0.06% 258
2025
Q4
$656K Sell
12,154
-200
-2% -$9.62K 0.01% 334
2025
Q3
$557K Hold
12,354
0.01% 350
2025
Q2
$572K Hold
12,354
0.01% 335
2025
Q1
$753K Sell
12,354
-100
-0.8% -$5.83K 0.01% 304
2024
Q4
$704K Sell
12,454
-146,200
-92% -$8.17M 0.01% 301
2024
Q3
$8.21M Hold
158,654
0.12% 153
2024
Q2
$6.59M Buy
158,654
+200
+0.1% +$8.95K 0.11% 165
2024
Q1
$8.59M Hold
158,454
0.13% 147
2023
Q4
$8.13M Hold
158,454
0.13% 144
2023
Q3
$9.2M Hold
158,454
0.15% 135
2023
Q2
$10.1M Buy
158,454
+15,000
+10% +$1.01M 0.16% 135
2023
Q1
$9.94M Buy
143,454
+21,550
+18% +$1.52M 0.16% 133
2022
Q4
$8.77M Sell
121,904
-28,000
-19% -$2.11M 0.14% 150
2022
Q3
$10.7M Sell
149,904
-52,250
-26% -$3.79M 0.18% 126
2022
Q2
$15.6M Sell
202,154
-837
-0.4% -$63.7K 0.25% 105
2022
Q1
$14.8M Buy
202,991
+45,112
+29% +$3.03M 0.21% 116
2021
Q4
$9.84M Buy
157,879
+38,750
+33% +$2.27M 0.14% 148
2021
Q3
$7.05M Buy
119,129
+9,600
+9% +$632K 0.1% 172
2021
Q2
$7.32M Hold
109,529
0.1% 166
2021
Q1
$6.92M Buy
109,529
+2,829
+3% +$176K 0.1% 157
2020
Q4
$6.62M Sell
106,700
-1,238
-1% -$76.1K 0.11% 157
2020
Q3
$6.51M Sell
107,938
-1,107
-1% -$66.6K 0.13% 145
2020
Q2
$6.41M Sell
109,045
-3,332
-3% -$199K 0.13% 138
2020
Q1
$6.26M Buy
112,377
+36,708
+49% +$2.24M 0.15% 127
2019
Q4
$4.86M Buy
75,669
+58,831
+349% +$3.37M 0.07% 167
2019
Q3
$854K Sell
16,838
-370
-2% -$17.4K 0.01% 271
2019
Q2
$780K Buy
17,208
+1,440
+9% +$67.1K 0.01% 286
2019
Q1
$752K Hold
15,768
0.01% 296
2018
Q4
$820K Sell
15,768
-225
-1% -$12.1K 0.01% 278
2018
Q3
$993K Hold
15,993
0.01% 302
2018
Q2
$885K Sell
15,993
-152
-0.9% -$8.21K 0.01% 308
2018
Q1
$1.02M Hold
16,145
0.01% 298
2017
Q4
$989K Buy
16,145
+400
+3% +$25K 0.01% 303
2017
Q3
$1M Buy
15,745
+522
+3% +$30.5K 0.01% 301
2017
Q2
$848K Sell
15,223
-531
-3% -$28.9K 0.01% 317
2017
Q1
$857K Hold
15,754
0.01% 362
2016
Q4
$921K Sell
15,754
-382
-2% -$20.9K 0.01% 309
2016
Q3
$870K Sell
16,136
-115
-0.7% -$7.39K 0.01% 302
2016
Q2
$1.2M Buy
16,251
+396
+2% +$28K 0.02% 270
2016
Q1
$1.01M Buy
15,855
+82
+0.5% +$5.17K 0.02% 277
2015
Q4
$1.08M Hold
15,773
0.02% 268
2015
Q3
$934K Hold
15,773
0.02% 289
2015
Q2
$1.05M Sell
15,773
-6,650
-30% -$438K 0.02% 283
2015
Q1
$1.45M Hold
22,423
0.03% 257
2014
Q4
$1.32M Hold
22,423
0.03% 265
2014
Q3
$1.15M Sell
22,423
-1,075
-5% -$53.7K 0.02% 265
2014
Q2
$1.14M Buy
23,498
+300
+1% +$14.8K 0.02% 272
2014
Q1
$1.21M Hold
23,198
0.03% 266
2013
Q4
$1.23M Sell
23,198
-2,600
-10% -$132K 0.03% 274
2013
Q3
$1.19M Sell
25,798
-23,200
-47% -$1.02M 0.03% 273
2013
Q2
$2.19M Buy
+48,998
New +$2.13M 0.05% 270

Other funds holding BMY

Thompson Siegel & Walmsley's BMY Position: Q2 2026 in Review

Thompson Siegel & Walmsley increased its Bristol-Myers Squibb (BMY) stake by 118% in Q2 2026, buying an estimated $3.79M and bringing the position to 121,984 shares worth $7.03M. The position accounts for 0.13% of the portfolio, ranked #185.

Thompson Siegel & Walmsley first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $15.6M in Q2 2022. 2,511 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Thompson Siegel & Walmsley held 121,984 shares of Bristol-Myers Squibb worth $7.03M as of Q2 2026.
  • Thompson Siegel & Walmsley bought 66,080 Bristol-Myers Squibb shares in Q2 2026, an estimated $3.79M.
  • Bristol-Myers Squibb made up 0.13% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #185 holding.
  • Thompson Siegel & Walmsley first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Thompson Siegel & Walmsley's Bristol-Myers Squibb position peaked at $15.6M in Q2 2022.
  • 2,511 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.